Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | -30.00K | -25.00K | -24.00K | -21.00K | EBIT |
0.00 | -21.27M | -14.00M | -13.65M | -12.70M | EBITDA |
0.00 | -19.31M | -13.98M | -13.62M | -12.24M | Net Income Common Stockholders |
-24.44M | -19.38M | -13.68M | -13.59M | -12.29M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
44.15M | 52.90M | 33.50M | 45.11M | 27.51M | Total Assets |
46.34M | 54.16M | 34.40M | 45.55M | 28.09M | Total Debt |
340.00K | 400.00K | 469.00K | 52.00K | 118.00K | Net Debt |
-2.69M | -4.14M | -4.26M | -4.66M | -7.29M | Total Liabilities |
5.63M | 3.10M | 2.57M | 1.53M | 2.08M | Stockholders Equity |
40.72M | 51.06M | 31.83M | 44.02M | 26.01M |
Cash Flow | Free Cash Flow | |||
-22.10M | -18.75M | -11.59M | -12.27M | -9.23M | Operating Cash Flow |
-22.08M | -18.73M | -11.51M | -12.25M | -9.19M | Investing Cash Flow |
8.56M | -18.30M | 11.54M | -20.54M | -16.13M | Financing Cash Flow |
11.99M | 36.84M | -6.00K | 30.09K | 28.84M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.78B | ― | -231.63% | ― | 42.53% | -15.29% | |
49 Neutral | $6.85B | 0.81 | -52.91% | 2.50% | 17.48% | 1.17% | |
48 Neutral | $398.26M | ― | -58.54% | ― | ― | -47.28% | |
48 Neutral | $195.91M | ― | -36.38% | ― | 88.63% | 18.78% | |
43 Neutral | $6.97M | ― | -248.97% | ― | ― | 57.83% | |
39 Underperform | $163.71M | ― | -53.27% | ― | ― | 2.53% |
On February 20, 2025, DiaMedica Therapeutics appointed Daniel J. O’Connor to its Board of Directors, recognizing his extensive experience in the biopharmaceutical industry. O’Connor’s leadership background, including his role in the acquisition of Ambrx Biopharma by Johnson & Johnson, positions him as a valuable asset to DiaMedica as it continues to advance its pipeline of treatments for acute ischemic stroke and preeclampsia.